Cargando…

Therapeutic Sequencing in ALK(+) NSCLC

Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK(+) NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigatinib have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elsayed, Mei, Christopoulos, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912146/ https://www.ncbi.nlm.nih.gov/pubmed/33494549 http://dx.doi.org/10.3390/ph14020080

Ejemplares similares

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
por: Xia, Guohao, et al.
Publicado: (2023)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
por: Golding, Brandon, et al.
Publicado: (2018)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
por: Meador, Catherine B., et al.
Publicado: (2023)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
por: König, David, et al.
Publicado: (2020)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
por: Noé, Johannes, et al.
Publicado: (2022)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r50drh0l6kqvl5js4iujo81oos